CRESCENT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
CRESCENT BIOPHARMA, INC. (CBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $12.64 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $9.11, a 85.54% increase year-over-year.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $4.91.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-12-31 was $4.86.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2015-03-31 was $5.10, a 16.80% decline year-over-year.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $8.27, a 455.03% increase from fiscal 2024.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $1.49, a 23.98% decline from fiscal 2023.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.96, a 157.89% increase from fiscal 2022.
- CRESCENT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $0.76, a 58.92% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.64 10-Q · filed 2026-07-30 | |||
| 2026-03-31 | $9.11 10-Q · filed 2026-04-29 | |||
| 2025-12-31 | $8.27 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $6.87 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $6.51 10-Q · filed 2026-07-30 | |||
| 2025-03-31 | $4.91 10-Q · filed 2026-04-29 | |||
| 2024-12-31 | $4.86 10-K · filed 2026-02-26 | $1.49 10-K · filed 2025-02-13 | ||
| 2023-12-31 | $1.96 10-K · filed 2025-02-13 | |||
| 2022-12-31 | $0.76 10-K · filed 2024-03-27 | |||
| 2021-12-31 | $1.85 10-K · filed 2024-03-27 | |||
| 2020-12-31 | $3.17 10-K · filed 2023-03-29 | |||
| 2019-12-31 | $7.17 10-K · filed 2022-03-03 | |||
| 2018-12-31 | $12.90 10-K · filed 2021-03-02 | |||
| 2015-09-30 | $5.09 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $5.10 10-Q · filed 2015-08-06 | |||
| 2015-03-31 | $5.10 10-Q · filed 2015-05-05 | |||
| 2014-12-31 | $6.70 10-K · filed 2015-03-16 | |||
| 2014-09-30 | $6.71 10-Q · filed 2015-11-12 | |||
| 2014-06-30 | $6.72 10-Q · filed 2015-08-06 | |||
| 2014-03-31 | $6.13 10-Q · filed 2015-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |